Baglin Trevor P, Carrell Robin W, Church Frank C, Esmon Charles T, Huntington James A
Department of Haematology, Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Hills Road, Cambridge CB2 2XY, United Kingdom.
Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11079-84. doi: 10.1073/pnas.162232399. Epub 2002 Aug 8.
The serine proteases sequentially activated to form a fibrin clot are inhibited primarily by members of the serpin family, which use a unique beta-sheet expansion mechanism to trap and destroy their targets. Since the discovery that serpins were a family of serine protease inhibitors there has been controversy as to the role of conformational change in their mechanism. It now is clear that protease inhibition depends entirely on rapid serpin beta-sheet expansion after proteolytic attack. The regulatory advantage afforded by the conformational mobility of serpins is demonstrated here by the structures of native and S195A thrombin-complexed heparin cofactor II (HCII). HCII inhibits thrombin, the final protease of the coagulation cascade, in a glycosaminoglycan-dependent manner that involves the release of a sequestered hirudin-like N-terminal tail for interaction with thrombin. The native structure of HCII resembles that of native antithrombin and suggests an alternative mechanism of allosteric activation, whereas the structure of the S195A thrombin-HCII complex defines the molecular basis of allostery. Together, these structures reveal a multistep allosteric mechanism that relies on sequential contraction and expansion of the central beta-sheet of HCII.
依次被激活以形成纤维蛋白凝块的丝氨酸蛋白酶主要受到丝氨酸蛋白酶抑制剂家族成员的抑制,这些抑制剂利用独特的β-折叠扩展机制来捕获并破坏其靶标。自从发现丝氨酸蛋白酶抑制剂是一个丝氨酸蛋白酶抑制家族以来,关于其机制中构象变化的作用一直存在争议。现在很清楚,蛋白酶抑制完全取决于蛋白水解攻击后丝氨酸蛋白酶抑制剂β-折叠的快速扩展。丝氨酸蛋白酶抑制剂构象灵活性所带来的调节优势在此通过天然和S195A凝血酶复合肝素辅因子II(HCII)的结构得以证明。HCII以糖胺聚糖依赖性方式抑制凝血酶,即凝血级联反应的最终蛋白酶,这涉及释放一个被隔离的水蛭素样N端尾巴以与凝血酶相互作用。HCII的天然结构类似于天然抗凝血酶,并提示了变构激活的另一种机制,而S195A凝血酶-HCII复合物的结构则定义了变构的分子基础。这些结构共同揭示了一种多步骤变构机制,该机制依赖于HCII中央β-折叠的顺序收缩和扩展。